The Patent Finder
ZR

Zoll Respicardia, Inc.

First filing 2006
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Respicardia, Inc. (to 2021)

32 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Nov 2027
Next term end
9
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Transvenous Phrenic Nerve Stimulation System US 10,406,366
Cited by 146 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Ends Aug 2029 · High confidence
Also notable
Respiratory Rectification US 8,233,987
Cited by 137 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Ends Oct 2031 · High confidence
Also notable
Medical Lead with Preformed Bias US 9,468,755
Cited by 92 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Ends Oct 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders (US 10,300,270) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Mar 10, 2027
    The maintenance fee for Transvenous Phrenic Nerve Stimulation System (US 10,406,366) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
  • 2 fees due Jun 1 to 17, 2027 · next Jun 1
  • 2 fees due Jul 9 to 28, 2027 · next Jul 9
  • 2 fees due Sep 29 to 30, 2027 · next Sep 29

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,305,119System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea
In force
 · High confidence
In forceHigh confidence
US 8,909,341Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders
In force
 · High confidence
In forceHigh confidence
US 9,744,351Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders
In force
 · Medium confidence
In forceMedium confidence
US 10,300,270Device and Method for the Treatment of Breathing Disorders and Cardiac Disorders
In force
 · Medium confidence
In forceMedium confidence
US 12,616,839System and Method to Modulate Phrenic Nerve to Prevent Sleep Apnea
In force
 · Medium confidence
In forceMedium confidence
US 12,179,014Transvenous Phrenic Nerve Stimulation System
In force
 · High confidence
In forceHigh confidence
US 12,558,539Detecting and Treating Disordered Breathing
In force
 · Medium confidence
In forceMedium confidence
US 9,199,075Transvascular Medical Lead
In force
 · High confidence
In forceHigh confidence
US 10,543,363Transvascular Medical Lead
In force
 · High confidence
In forceHigh confidence
US 11,389,648Transvascular Medical Lead
In force
 · High confidence
In forceHigh confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 1 patent in force now held by others · 1 patent ended · 11 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited